Drug Details
| General Information of the Drug (ID: DR9750) | ||||
|---|---|---|---|---|
| Name |
BRD4770
|
|||
| Synonyms |
BRD4770; 1374601-40-7; Methyl 2-benzamido-1-(3-phenylpropyl)-1H-benzo[d]imidazole-5-carboxylate; BRD 4770; BRD-4770; methyl 2-benzamido-1-(3-phenylpropyl)benzimidazole-5-carboxylate; C25H23N3O3; GTPL7016; AOB3886; CHEMBL3970748; SCHEMBL16569005; EX-A692; CHEBI:131143; BDBM225263; BCP10433; 2282AH; MFCD23143627; NSC777671; s7591; ZINC95099914; AKOS026750266; BRD 4770;BRD-4770; CCG-268804; CS-3446; NSC-777671; SB19344; NCGC00351780-01; NCGC00351780-04; AS-16771; DA-35008; HY-16705; BRD4770, >=98% (HPLC); FT-0733814; A14401; J-690148; BRD-K72264770-001-01-6; Q27075478; methyl 2-benzamido-1-(3-phenylpropyl)-1H-1,3-benzodiazole-5-carboxylate; Methyl-2-(benzoylamino)-1-(3-phenylpropyl)-1H-benzimidazole-5-carboxylate; 2-(Benzoylamino)-1-(3-phenylpropyl)-1H-benzimidazole-5-carboxylic acid methyl ester
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Pancreatic cancer [ICD-11: 2C10] | Investigative | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C25H23N3O3
|
|||
| PubChem CID | ||||
| Canonical SMILES |
COC(=O)C1=CC2=C(C=C1)N(C(=N2)NC(=O)C3=CC=CC=C3)CCCC4=CC=CC=C4
|
|||
| InChI |
1S/C25H23N3O3/c1-31-24(30)20-14-15-22-21(17-20)26-25(27-23(29)19-12-6-3-7-13-19)28(22)16-8-11-18-9-4-2-5-10-18/h2-7,9-10,12-15,17H,8,11,16H2,1H3,(H,26,27,29)
|
|||
| InChIKey |
UCGWYCMPZXDHNR-UHFFFAOYSA-N
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Gossypol | Gossypium herbaceum | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Increase | Autophagosome formation | ||||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| HPAC | CVCL_3517 | Pancreatic adenocarcinoma | Homo sapiens | |||
| PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | |||
| PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
The combination of gossypol and BRD4770 increased LC3-II levels and the autophagosome number in PANC-1 cells, and the compound combination appears to act in a BNIP3-dependent manner, suggesting that these compounds act together to induce autophagy-related cell death in pancreatic cancer cells. | |||||
